FINSUM
Putnam Warns Fresh Stimulus is a Huge Risk to Markets
(New York)
Despite all fears, markets had a fairly strong year in 2020. Why? See the full story on our partner Magnifi’s site.
ESG Investing is Beating the S&P 500
(New York)
For those paying attention, ESG has had a great run over the last year. While many may feel that in an intangible way, the real world results are strong too, with ESG investments outperforming the S&P 500 by 1.3% in 2020. ESG investment experienced some solid outperformance early in the pandemic because if its natural defensive. Millennials appear to be driving the trend, which seems likely to only increase. More generally, the environment has become a major focus for both retail investors and major asset managers, like BlackRock, which has helped make the sector mainstream.
FINSUM: Our best call for ESG is that it will do great in 2021. The main reason being that the Biden administration is bringing a strong and renewed focus on the environment, which will both awaken public consciousness but also give ESG some favorable regulatory tailwinds.
The Best ETFs for Buying Into the Ecommerce Surge
(New York)
One year ago you could have easily said that brick and mortar retail was effectively dead, or at least had a very bleak…See the full story on our partner Magnifi’s site.
Why it is a Good Time to Buy into Cloud Computing
(Silicon Valley)
If you dig under the handful of headlines which have driven financial media during the pandemic, you will find a sub-narrative...See the full story on our partner Magnifi’s site.
Goldman Says This is the Biggest Risk to Markets in 2021
(New York)
Goldman Sachs has been one of the biggest bulls on the street so far in 2021. The bank is calling for 6.6% GDP growth and a strong year for the S&P 500. However, in the last week they have been backtracking a bit and pointing out some of the key risks to the economy and market. Whether or not investors like it, Goldman has a very clear risk risk—COVID variants. The bank says that if the new variants make the current vaccine ineffective, then all bets for the market are off. Based on the current science, that seems unlikely to happen. But nonetheless, there are intermediate risks, such as the new variants slowing down herd immunity or making consumers more fearful about going out/spending/the economy, both of which could have unforeseen negative consequences on the economy.
FINSUM: The new virus strains are a big risk. While the current vaccines don’t seem likely to be rendered useless, consumer fear of the new variants could slow down the recovery. Notably, Goldman says its baseline forecasts don’t include any of these eventualities.